Showing results (251-260 of 470) with videos related to
Sort By:
Pageof 47
Nature Communications|June 7, 2023
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerTakayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data setAimery de Gramont, Joleen Hubbard, Qian Shi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal CancerAxel Grothey, Jonathan R Strosberg, Lindsay A Renfro, et al.Journal of Clinical Pharmacology|March 31, 2022
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid TumorsEmily J Koubek, Andrew T Ralya, Thomas R Larson, et al.International Journal of Oncology|June 10, 2016
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapyJae-Hyun Park, Miran Jang, Yunus Emre Tarhan, et al.The Oncologist|April 4, 2020
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative GroupHumaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2023
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal CancerEric Van Cutsem, Julien Taieb, Rona Yaeger, et al.Breast Cancer Research and Treatment|March 16, 2006
Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52James N Ingle, Vera J Suman, James A Mailliard, et al.Clinical Breast Cancer|February 5, 2020
Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG)Muaiad Kittaneh, Sunil Badve, Humberto Caldera, et al.Molecular Cancer Therapeutics|September 1, 2018
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast CancerXinyi Tu, Mohamed M Kahila, Qin Zhou, et al.Pageof 47